Peter Muller, Managing Director, Schlafender Hase,
Americas, says “Bringing a new drug to market costs millions,
so it’s highly risky to leave product labelling and packaging
to chance. Especially if it’s expensive professionals giving
hours of their time to these repetitive manual processes.”
With his 20 years of working experience in software and
process improvement, in this article he focuses on the cost of
corrections in clinical trials labelling.